TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3431880

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 31268194

Group type: EXPERIMENTAL
Intervention: Individualized fortification (IF) group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Standard fortification group
Number of subjects: 51
Study: 28272119

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 198
Study: 27787895

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided, single-injection, femoral nerve block followed by continuous fascia iliaca block
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional analgesics
Number of subjects: 161
Study: 24987525

Group type: EXPERIMENTAL
Intervention: Intervention - Raising the salience of personal investment in weight-loss surgery
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Intervention - Weight loss measurement
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control - Weight loss measurement
Number of subjects: 91
Study: 23109014

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: LPV/r-based HAART
Number of subjects: 30
Study: 20232607

Group type: EXPERIMENTAL
Intervention: Weekly paired physical activity and nutrition messages via e-mail for 12 weeks
Number of subjects: 1043

Group type: COMPARATOR
Intervention: Bulk e-mail messages at the conclusion of the intervention (Control)
Number of subjects: 1043
Study: 18416885

Group type: EXPERIMENTAL
Intervention: Collagen hydrolysate (CH) 10 g in 25 mL liquid formulation
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (25 mL liquid containing xanthan)
Number of subjects: 147
Study: 15665549

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 400 mg three times a day for 2 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Captopril 25 mg three times a day for 2 months
Number of subjects: 39
Study: 11839142

Group type: EXPERIMENTAL
Intervention: NRTI + protease inhibitor
Number of subjects: 0
Study: 10084409

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) 4.5 g i.v. every six hours (n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C) 500 mg i.v. every six hours (n = 75)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Imipenem/cilastatin (I/C)
Number of subjects: 150
Study: 7781402

Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy (50 to 60 Gy recommended)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic cranial irradiation (PCI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative thoracic radiation fractionation schedules (accelerated hyperfractionation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concurrent and alternating chemotherapy strategies
Number of subjects: 0
Study: 1685506

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Ampicillin-plus-metronidazole
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no chemoprophylaxis)
Number of subjects: 163
Study: 6650444

Group type: EXPERIMENTAL
Intervention: Dietary treatment of 400 mg cholesterol per day with exercise (MX)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Dietary treatment of 1400 mg cholesterol per day with exercise (HX)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Dietary treatment of 1400 mg cholesterol per day without exercise (HS)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combined exercise and sedentary group data at each level of dietary cholesterol
Number of subjects: 23
Study: 30720850

Group type: COMPARATOR
Intervention: Single use dialyzers (10 HD sessions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dialyzer reuse (30 HD sessions)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dialyzer reuse
Number of subjects: 10
Study: 28787388

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (2 daily oral doses of 2 × 10 CFUs for 5 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo (2 daily doses for 5 days)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 26906708

Group type: EXPERIMENTAL
Intervention: Balloon catheter dilatation
Number of subjects: 189

Group type: COMPARATOR
Intervention: Nasolacrimal duct intubation
Number of subjects: 189
Study: 24214140

Group type: EXPERIMENTAL
Intervention: Topical brimonidine (0.2 %) twice daily for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 30
Study: 22303998

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (sleep education and counseling session)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control (no psychoeducational intervention)
Number of subjects: 236
Study: 20069963

Group type: EXPERIMENTAL
Intervention: Vitro ceramic
Number of subjects: 15

Group type: COMPARATOR
Intervention: Composite resin
Number of subjects: 15
Study: 17450962

Group type: EXPERIMENTAL
Intervention: Simultaneous skilled model observation and self-modeling
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 53
Study: 15150726

Group type: EXPERIMENTAL
Intervention: Modified-live virus combination vaccine, subcutaneous vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonvaccinated controls
Number of subjects: 0
Study: 11772828

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block with 10 mL of 0.5% bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Suprascapular nerve block with 10 mL of 0.9% saline (placebo)
Number of subjects: 30
Study: 10518850

Group type: EXPERIMENTAL
Intervention: Active unit (electronic anesthesia)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control unit (non-working electronic anesthesia)
Number of subjects: 100
Study: 7807622

Group type: EXPERIMENTAL
Intervention: Case management using trained community health workers with thrice weekly home visits and treatment based on WHO recommendations
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Referral system established from the community to a tertiary centre
Number of subjects: 481
Study: 2561409

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 4 mg daily by inhalation)
Number of subjects: 117
Study: 326301

Group type: EXPERIMENTAL
Intervention: Topical atenolol (1%, 2%, and 4%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31813384

Group type: EXPERIMENTAL
Intervention: High-oleic peanuts (56 g) within a hypoenergetic diet
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Conventional peanuts (56 g) within a hypoenergetic diet
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (hypoenergetic diet without peanuts)
Number of subjects: 64
Study: 30913926

Group type: EXPERIMENTAL
Intervention: Calm nature films during colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard examination room without films)
Number of subjects: 0
Study: 29073603

Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass (CCAB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Off‐pump coronary artery bypass grafting (OPCAB)
Number of subjects: 30
Study: 25149179

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MPONE) 20 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Prednisone (PN) 25 mg
Number of subjects: 52
Study: 22999778

Group type: EXPERIMENTAL
Intervention: Intravenous phenobarbital (10 mg/kg in 100 mL normal saline)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo (100 mL normal saline)
Number of subjects: 102
Study: 21516008

Group type: EXPERIMENTAL
Intervention: Heat therapy using a far infrared rays heating element
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no heat therapy)
Number of subjects: 48
Study: 18068281

Group type: EXPERIMENTAL
Intervention: Erythropoietin +/- granulocyte-colony-stimulating factor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (azacytidine and decitabine)
Number of subjects: 0
Study: 17302078

Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with tidal volume breathing (n=15)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sevoflurane administered with vital capacity breaths (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both groups (tidal volume and vital capacity)
Number of subjects: 30
Study: 12900681

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment applied at LI 4, ST 36 for 20 min, and ST 6, LU 6 for 15 min, 4 hours after the game every night during the competition period
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no acupuncture treatment)
Number of subjects: 21
Study: 11180018

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg daily for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9366624

Group type: EXPERIMENTAL
Intervention: Self-report baseline questionnaire (BQ)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: History of Hormone Use interview (HHU) at the 3-month follow-up visit (HHU3mos)
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: History of Hormone Use interview (HHU) at the 3-year follow-up (HHU3yrs)
Number of subjects: 863
Study: 8264146

Group type: EXPERIMENTAL
Intervention: Physiological cortisol supplementation (20 mg 3 hr prior to test, and 1 mg/hr during test) in panhypopituitarism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological cortisol supplementation in Addison's disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg 3 hr prior to test, and 0.03 mg/hr during test) in Addison's disease
Number of subjects: 0
Study: 2984235

Group type: EXPERIMENTAL
Intervention: Morphine sulfate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30105441

Group type: EXPERIMENTAL
Intervention: Usual care plus use of the IncoStress device
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 80
Study: 30652487

Group type: EXPERIMENTAL
Intervention: Soil amendments (limestone, organic compost, Ca silicate, zeolite)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Zeolite and Ca silicate amendments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control treatment (no amendments)
Number of subjects: 0
Study: 26789012

Group type: EXPERIMENTAL
Intervention: Low-glucose suspend (LGS) feature
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (LGS turned off)
Number of subjects: 60
Study: 24219012

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg once weekly
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 273
Study: 22669332

Group type: EXPERIMENTAL
Intervention: Ral 60 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ral 30 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: n-3FA (Lovaza) 4 g
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Lovaza 4 g + Ral 30 mg
Number of subjects: 46

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 46
Study: 20055694

Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcipotriol (Cp) monotherapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Betamethasone dipropionate (BD) monotherapy
Number of subjects: 18
Study: 18678843

Group type: EXPERIMENTAL
Intervention: Combination therapy (tolterodine + behavioral training)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Drug therapy alone (tolterodine)
Number of subjects: 307
Study: 15959750

Group type: EXPERIMENTAL
Intervention: Neurophysiological parameters (EAEP, VEP, MSEP, TSEP, MEP)
Number of subjects: 0
Study: 12855088

Group type: EXPERIMENTAL
Intervention: VRSA (virtual stress assessment scenario with a behaviorally realistic motion controlled avatar with sonic feedback)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: VRFP (virtual stress assessment scenario relative to a first-person perspective)
Number of subjects: 90

Group type: COMPARATOR
Intervention: NTC (No Treatment Condition, just an interview)
Number of subjects: 90
Study: 10476617

Group type: EXPERIMENTAL
Intervention: Ozagrel Hydrochloride (400 mg/day, orally)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8724617

Group type: EXPERIMENTAL
Intervention: 400 micrograms of oral misoprostol every 3 hours up to 5 doses
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 mg of vaginal gemeprost every 6 hours up to 4 doses
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (misoprostol and gemeprost)
Number of subjects: 50
Study: 1680266

Group type: COMPARATOR
Intervention: Midazolam 4-5 mg, intramuscularly
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Ketobemidone (Ketogan) 1-1.5 ml
Number of subjects: 100
Study: 6299682

Group type: EXPERIMENTAL
Intervention: 30 mg of THC for 14 nights
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo during four baseline nights and four withdrawal nights
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo during entire period for the second subject
Number of subjects: 2
Study: 31090161

Group type: EXPERIMENTAL
Intervention: Transtheoretical model-based motivational interview
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 28729311

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 160
Study: 26434686

Group type: EXPERIMENTAL
Intervention: Polyvalent Bacterial Lysate (PBL)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Autovaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study: 24043299

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: On-treatment CRP levels
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: On-treatment low-density lipoprotein cholesterol levels
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Log change in CRP
Number of subjects: 985
Study: 20101166

Group type: EXPERIMENTAL
Intervention: Tumor size exceeding 4.5 cm
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Optimal cut-off values for tumor size
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Tumor size as a prognostic parameter
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Median follow-up of 45 months
Number of subjects: 359
Study: 19351691

Group type: EXPERIMENTAL
Intervention: Myocardial Infarction (MI) within 30 days of randomization
Number of subjects: 13819

Group type: EXPERIMENTAL
Intervention: Major Bleeding within 30 days of randomization
Number of subjects: 13819
Study: 19114736

Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 20
Study: 15269191

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 5 days
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Telithromycin 800 mg once daily for 7 days
Number of subjects: 575

Group type: COMPARATOR
Intervention: Clarithromycin 500 mg twice daily for 10 days
Number of subjects: 575
Study: 11351289

Group type: EXPERIMENTAL
Intervention: Intense noise exposure in subjects with asymmetrical hearing loss
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intense noise exposure in subjects with symmetrical hearing loss
Number of subjects: 258
Study: 9226311

Group type: EXPERIMENTAL
Intervention: 20 Gy neon ion irradiation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 25 Gy neon ion irradiation
Number of subjects: 15
Study: 7971542

Group type: EXPERIMENTAL
Intervention: Computer-assisted self-care program for colds and flu
Number of subjects: 454

Group type: COMPARATOR
Intervention: Non-users (control group)
Number of subjects: 454
Study: 3296867

Group type: EXPERIMENTAL
Intervention: Albuterol (5 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Metaproterenol (15 mg)
Number of subjects: 20
Study: 31402563

Group type: EXPERIMENTAL
Intervention: Lateral injection points performed first
Number of subjects: 12

Group type: COMPARATOR
Intervention: Medial injection points performed first
Number of subjects: 12
Study: 29234138

Group type: EXPERIMENTAL
Intervention: Er:YAG laser + HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser + HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphite + Er:YAG laser + HF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphite + Nd:YAG laser + HF
Number of subjects: 0

Group type: COMPARATOR
Intervention: HF (hydrofluoric acid-etching)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graphite coating
Number of subjects: 0
Study: 25022932

Group type: EXPERIMENTAL
Intervention: Intracoronary Abciximab
Number of subjects: 89

Group type: COMPARATOR
Intervention: Intravenous Abciximab
Number of subjects: 89
Study: 24330347

Group type: EXPERIMENTAL
Intervention: General practice-based vascular risk factor intervention
Number of subjects: 384

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 384
Study: 21541874

Group type: EXPERIMENTAL
Intervention: Monthly mystery shop reports with feedback communications (twice monthly)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Twice-monthly mystery shop reports with feedback communications
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 45
Study: 18460563

Group type: EXPERIMENTAL
Intervention: GH (0.5 mg iv)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH blockade (pegvisomant 30 mg sc)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GH infusion (45 ng/kg.min, 5.5 h)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 17070267

Group type: EXPERIMENTAL
Intervention: 1 mg nociceptin/orphanin FQ in 10 cc saline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (saline) solution
Number of subjects: 18
Study: 15342616

Group type: EXPERIMENTAL
Intervention: 8 patches
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 patches
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2 patches
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4 and 8 patches
Number of subjects: 24
Study: 11698834

Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Morphine (0.3 mg/kg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clonidine (1.5 microg/kg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 150
Study: 9540175

Group type: EXPERIMENTAL
Intervention: RCT + A (amifostine 500 mg prior to carboplatin)
Number of subjects: 39

Group type: COMPARATOR
Intervention: RCT alone
Number of subjects: 39
Study: 7516250

Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 9
Study: 2660992

Group type: EXPERIMENTAL
Intervention: SR IS-5-MN 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31902294

Group type: EXPERIMENTAL
Intervention: Hand paddles (HPD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 20
Study: 31664940

Group type: EXPERIMENTAL
Intervention: Sertraline treatment for 12 weeks
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: MDD+/CKD+ patients
Number of subjects: 175

Group type: COMPARATOR
Intervention: MDD-/CKD+ patients
Number of subjects: 175
Study: 29179693

Group type: COMPARATOR
Intervention: Control shoes
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Unloading shoes
Number of subjects: 34
Study: 25512670

Group type: EXPERIMENTAL
Intervention: Captain-led and poster STI screening promotion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexual health advisor-led and poster STI screening promotion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Poster-only STI screening promotion
Number of subjects: 0
Study: 23562090

Group type: COMPARATOR
Intervention: Canakinumab (2 mg/kg, max 300 mg) monthly for 12 months
Number of subjects: 138

Group type: COMPARATOR
Intervention: Anakinra (100 mg) daily for 9 months
Number of subjects: 138
Study: 21513812

Group type: EXPERIMENTAL
Intervention: Raloxifene (60mg/day)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HRT (estriol plus medroxyprogesterone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no medications)
Number of subjects: 32
Study: 19761455

Group type: EXPERIMENTAL
Intervention: Self‐Evaluated Core Competencies Scale (used for assessment)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Principal components analysis with varimax rotation
Number of subjects: 802
Study: 16466708

Group type: EXPERIMENTAL
Intervention: B-vitamin supplements (pyridoxine, riboflavin, and folic acid) for 30 days
Number of subjects: 32
Study: 14716707

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CYP2D6 PMs
Number of subjects: 125

Group type: COMPARATOR
Intervention: CYP2D6 EMs
Number of subjects: 125
Study: 11300432

Group type: COMPARATOR
Intervention: Aspirin (160 mg/day)
Number of subjects: 1470

Group type: EXPERIMENTAL
Intervention: Ticlopidine (500 mg/day)
Number of subjects: 1470
Study: 9868087

Group type: EXPERIMENTAL
Intervention: Enalapril, CoQ10, and VitE
Number of subjects: 50

Group type: COMPARATOR
Intervention: CoQ10 and VitE
Number of subjects: 50
Study: 8280822

Group type: EXPERIMENTAL
Intervention: Ranitidine continuous i.v. infusion (6.25 mg/h)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Famotidine bolus injection (20 mg every 12 h)
Number of subjects: 28